AI-Assisted Pathology Poised to Transform Liver Disease Care
Medscape Medical News
Media Coverage
Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress
Madrigal Pharmaceuticals Press Release
Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™
Madrigal Pharmaceuticals Press Release
Singapore: A Myriad of Biotech Financing Strategies
Precision diagnostics firm Histoindex began life as a spinoff from A*STAR and so received funding from the Singaporean government as well as from angel investors, corporations, and institutions. Co-founder and CEO, Dr. Gideon Ho, highlights Singapore’s advantages for innovative start-up firms looking to grow in Singapore.
A proprietary biophotonics technology and platform for stain-free AI-based digital pathology
Dr Gideon Ho, co-founder and CEO of HistoIndex, shares the story of the company’s establishment in 2010, their proprietary technology to provide the world’s first stain-free AI-driven biopsy and tissue analysis focused on the diagnosis of fibrosis and cancer, and his thoughts on the Singaporean healthcare start-up ecosystem.
Behind the Success of Singapore’s Healthcare and Biomedical Startups
Singapore has always been regarded as a hotspot for startup growth and innovation.
SGH develops test that achieves consistency, accuracy in measuring the extent of fatty liver
A Singapore General Hospital (SGH) team, in collaboration with HistoIndex, has developed an automated test for quantifying fatty liver disease.